(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 December 2020 (17.12.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/249970 A1

(51) International Patent Classification:
C07D 498/22 (2006.01) *A61P 25/06* (2006.01)
A61K 31/438 (2006.01)

(21) International Application Number:
PCT/GB2020/051429

(22) International Filing Date:
12 June 2020 (12.06.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1908430.0 12 June 2019 (12.06.2019) GB

(71) Applicant: **HEPTARES THERAPEUTICS LIMITED** [GB/GB]; Granta Park, Great Abington, Cambridge CB21 6DG (GB).

(72) Inventors: **BROWN, Giles Albert**; Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge CB21 6DG (GB). **CONGREVE, Miles Stuart**; Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge CB21 6DG (GB). **WATSON, Stephen Paul**; Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge CB21 6DG (GB). **CANSFIELD, Julie**; Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge CB21 6DG (GB). **O'BRIEN, Michael Alistair**; Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge CB21 6DG (GB). **DEFLORIAN, Francesca**; Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge CB21 6DG (GB). **OTT, Gregory R.**; Teva Pharmaceuticals, 1090 Horsham Road, North Wales, Pennsylvania 19454 (US). **SWAIN, Nigel Alan**; Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge CB21 6DG (GB). **CANSFIELD, Andrew David**; Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge CB21 6DG (GB).


(74) Agent: **STRATAGEM INTELLECTUAL PROPERTY MANAGEMENT LIMITED**; Meridian Court, Comberton Road, Toft, Cambridge Cambridgeshire CB23 2RY (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) **Title:** CGRP ANTAGONIST COMPOUNDS



(1a);

(57) **Abstract:** The disclosures herein relate to novel compounds of Formula (1a): and salts thereof, wherein W, Z, L, $R^1$and R^2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.

WO 2020/249970 A1